Skip to content
Purdue Institute for Cancer Research
Home
About Us
Our History
Membership
Directory
Cell Identity and Signaling
Targets, Structures and Drugs
Drug Delivery and Molecular Sensing
Research
Tyler Trent Pediatric Cancer Research Center
Scientific Programs
Shared Resources
Research Funding
Internal Funding Opportunities
Pilot Grants Program Calendar
Recognition Awards
Faculty Support
Research Impact Areas
Adult & Common Cancers
Pediatric & Rare Cancers
Drug Discovery & Treatment
Prevention & Detection
Personalized Medicine
Veterinary Medicine
Training & Education
Undergraduate Students
Graduate and Doctoral Students
Postdoctoral Fellows
T32 Training Grant Programs
Dual-Title PhD in Cancer Research
News & Stories
News
Stories & Highlights
Events
Upcoming Events
Cancer Research Day
Hammer Down Cancer
2026 5K Challenge
Community Partners
Indiana Elks Association
Walther Cancer Foundation
Paula And Rodger Riney Foundation
Zeta Tau Alpha
Join the Fight
Give now
CLOSE
Purdue Institute for Cancer Research
Search
Home
About Us
Our History
Membership
Directory
Cell Identity and Signaling
Targets, Structures and Drugs
Drug Delivery and Molecular Sensing
Research
Tyler Trent Pediatric Cancer Research Center
Scientific Programs
Shared Resources
Research Funding
Internal Funding Opportunities
Pilot Grants Program Calendar
Recognition Awards
Faculty Support
Research Impact Areas
Adult & Common Cancers
Pediatric & Rare Cancers
Drug Discovery & Treatment
Prevention & Detection
Personalized Medicine
Veterinary Medicine
Training & Education
Undergraduate Students
Graduate and Doctoral Students
Postdoctoral Fellows
T32 Training Grant Programs
Dual-Title PhD in Cancer Research
News & Stories
News
Stories & Highlights
Events
Upcoming Events
Cancer Research Day
Hammer Down Cancer
2026 5K Challenge
Community Partners
Indiana Elks Association
Walther Cancer Foundation
Paula And Rodger Riney Foundation
Zeta Tau Alpha
Join the Fight
Give now
Home
»
In the news
»
Compound developed by PICR member emeritus Mark Cushman advances to Phase 2 trial for recurrent glioblastoma
February 26, 2026
Compound developed by PICR member emeritus Mark Cushman advances to Phase 2 trial for recurrent glioblastoma